Freed's Doctor-Led Growth Strategy
Freed at $13M ARR
Freed’s edge is not better access to hospital CIOs, it is a cheaper and faster path to the doctor who feels the paperwork pain every day. At $99 per month, Freed can be bought by a solo doctor or small clinic without a long sales cycle, which helped it reach $13M ARR by August 2024 with only four salespeople. Abridge and Nuance win through deep EHR and health system relationships, while Freed wins by being easy to start using before IT gets involved.
-
Freed is aimed at practices with fewer than 10 doctors, a segment that represents 47% of U.S. clinicians. In that setting, the user is often also the buyer, so the product can spread one doctor at a time instead of waiting for a hospital wide contract.
-
Abridge took the opposite route. It went deep with Epic and later Athenahealth, grew to more than 60,000 clinicians across 100 plus health systems, and reached an estimated $100M ARR by May 2025. That scale came with heavier partnerships, integration work, and enterprise selling.
-
The tradeoff is that healthcare PLG has a ceiling. Once a scribe needs to write directly into the EHR for larger groups, the sale starts running through IT, compliance, and business associate agreements. That favors enterprise incumbents with deeper integrations, while Freed’s model works best at the fragmented small practice end.
The next phase is a climb from lightweight note capture into deeper workflow. Freed has already shown that a self serve scribe can become a real business, and the path forward is to turn that doctor level adoption into more integrated products like pre charting, coding, and payments, without losing the speed and affordability that made the initial wedge work.